Empatica is a full-stack digital healthcare company and a pioneer in digital biomarker development and continuous patient monitoring driven by AI.
Empatica’s platform consists of medical-grade smartwatches, software, and physiological and behavioural digital biomarkers. Together they enable the continuous remote monitoring of human health across a range of conditions, via clinical-quality digital measurements.
Empatica’s solutions are currently being used by thousands of research partners, institutions, and patients, to run decentralized clinical trials, develop novel digital biomarkers, conduct academic research with real-world data, and monitor neurological conditions.
Aparito is a global health tech company that brings clinical trials to patients and unlocks real-world data through mobile apps, video assessments & wearable devices.
We provide innovative, comprehensive patient-centric solutions that integrate required clinical & regulatory expertise to capture patient data and develop digital endpoints for both hybrid and decentralised clinical trials.
At Aparito we believe in improving patient experience in clinical trials to provide better outcomes in clinical research.
The Digital Medicine Society (DiMe) is a global non-profit and the professional home for all members of the digital medicine community. Together, we drive scientific progress and broad acceptance of digital medicine to enhance public health.
The COVID-19 public health emergency shifted a number of protocols and operating plans for clinical research and care alike. As more trials and care shift to the home, convening folks working on these problems in a common summit will help us ensure that more high quality measures support patients at home.
Digital Biomarkers & Digital Measurements Summit is ideally timed to enable critical conversations between stakeholders enabling the progression of medicine toward a patient-oriented, decentralized, tech-enabled future.
Continuing the conversation from last year, the Digital Biomarkers & Digital Measurement Summit is once again providing the platform to bring together key stakeholders who are driving digital innovation within healthcare. I’m excited to learn from leaders in the space and collaboratively advance this exciting field.
The Digital Biomarkers event is a critical place to learn, evaluate, and “take inventory” in an industry that is the front door to enabling the promise of precision medicine. I’m particularly intrigued to learn about how innovators are thinking about the validation of digital biomarkers to be used as clinical endpoints, then how they can be embedded into digital therapeutics for real-world use.
The Digital Biomarkers & Digital Measurements Summit is back with a bang! Bringing you 2 full days of cutting-edge content and an industry leading speaker faculty, this event provides you with a one-stop shop of all things digital biomarkers & digital measurements ensuring you leave the event with key takeaways and the knowledge to accelerate your own digital journey. We’ve got a lot to catch up on and this Summit has got you covered!
Starting with the differences between digital biomarkers, measurements and endpoints, through to commercialization, this Summit will provide you with a truly end-to-end learning experience. Learning is at the heart of the agenda and through a variety of dynamic formats, you will be able to accelerate your understanding of the industry in just two days.
Digital biomarkers and digital measurements have long been explored but with the recent changes to healthcare and pharma, there is greater interest than ever before in what they can offer. This Summit will help define this new wave of the industry through exclusive discussions with the movers and shakers, and this is your chance to be part of them.
2022 Speaker Faculty
Benjamin (Ben) Vandendriessche is Chief Medical Officer at Byteflies, the Belgian-American company behind Sensor Dot, a powerful platform for 24/7 capture of medical insights to deliver care at home and augment clinical trials with real-world data.
He trained in molecular biology, systems physiology, and data analytics for physiologic waveform and vital sign processing. He completed a PhD in molecular biology at Ghent University as an IWT Fellow, followed by a postdoc in critical care medicine at Case Western Reserve University (CWRU) as a BAEF Fellow. He joined Byteflies in 2016, is adjunct assistant professor at CWRU, and co-chair of the Digital Medicine Society (DiMe) research committee.
Siddharth completed his PhD at the University of Oxford, where he is currently based as a Departmental Lecturer. His research focuses on developing healthcare technologies that can assist with remote detection and monitoring of neurodegenerative diseases. He has been working on a smartphone app that helps assess the symptoms of Parkinson’s disease, by analysing voice/balance/gait/finger tapping/reaction time/rest and postural tremor, which are recorded using the inbuilt smartphone sensors. He has worked with the NHS, and his research has been published in academic journals including Cerebral Cortex, Neurology, Parkinsonism & related disorders, Physiological measurement, Brain communications, Annals of clinical and translational neurology, to name a few. He was the recipient of the Martin Black Prize and the EPSRC Network on Computational Statistics and Machine Learning (NCSML) award. The applications of his work primarily lie in telemedicine and emergency healthcare.
Since 2000, Kai has been a pioneer in patient-facing solutions for clinical trials working with
young innovative technology companies. In 2012, Kai co-founded eClinicalHealth, the
developers of the Clinpal remote clinical trial platform. Through his involvement in technical,
operational and scientific roles, he has gained deep understanding of broad aspects of the
patient journey in clinical trials from recruitment and engagement through data capture.
Kai brings his innovation mindset and ways of working to support Janssen’s global
regulatory policy work across a range of topics. Kai has a passion for broad pre-competitive
collaboration and is motivated to modernize the ways our broader ecosystem works together to advance the adoption of novel tools and methods to support efficient and
patient-centric pharmaceutical R&D.
Matteo Lai is co-founder and CEO of Empatica, a digital biomarker and medical devices company based in Boston, Massachusetts, and Milan, Italy. Empatica provides an end-to-end remote health monitoring platform for collecting clinical-quality data in decentralized clinical trials, and develops digital biomarkers that can monitor a range of conditions.
As a technology entrepreneur, Mr. Lai has critically contributed to the invention of the solutions being offered by Empatica. His company has developed the award-winning Embrace, which became the world’s first FDA cleared smart watch for use in Neurology. Its latest EmbracePlus wearable, which he also co-designed, is the world’s smallest and most advanced wearable sensor suite for research.
Matteo studied Engineering, trained as an Architect, and holds a Double MSc degree in Architecture and a Master’s in Innovation Management. He is a contributor to DiMe, and was recently selected by Sifted as one of the top pioneers of the European startup world.
Katrine has been with Biogen since 2013 and is currently the Head of Payer & Health Ecosystem Value and Strategy in Biogen Digital Health (BDH). She is responsible for ensuring that the payer and health ecosystem perspectives and needs are integral parts of strategies and activities in BDH. For the past 18 years, Katrine has almost uniquely focused on bringing the payer perspective into the pharma industry. Prior to joining the BDH team, Katrine was responsible for securing the European Payer Insights into pipeline assets most prominently gene therapies in ophthalmology, ALS and depression. In 2018 she was amongst the first to start the preparations for Alzheimer’s Disease treatments Europe, spearheading the system readiness and cross-functional ecosystem preparations. Katrine joined Biogen to support the European launch of two products for Multiple Sclerosis, but has since managed to work on all Biogen marketed products. She has excelled in updating and formalizing internal market access alignment processes; continuously striving to ensure focus on patients and payers.
Throughout her career she has launched 7 products in areas as different as Hodgkin’s Lymphoma and Short Bowel Syndrome to new Insulins, and COPD products. Katrine began her career with the Global Strategic Pricing and Reimbursement team in Novo Nordisk headquarters in Denmark and has since held various positions in Value and Access teams in Nycomed, Takeda and Biogen. Katrine earned a Master of Science in Health Economics and a bachelor’s in International Business, Language and Culture both from University of Southern Denmark
Carrie Northcott, PhD is a Director/ Project Lead within Digital Medicine and Translational Imaging (DMTI), Early Clinical Development (ECD) at Pfizer.
She leads a driven and diverse team that is evaluating and validating the use of
wearable digital devices to more fully understand and characterize physiological endpoints, such as quantitatively measuring night-time scratch and sleep. Carrie has a diverse scientific background in Pharmacology,
Toxicology, and Physiology which provides unique insight into understanding
how these novel digital endpoints provide meaningful information to patients, doctors and researchers to better treat and understand diseases.
Bert is an experienced Senior Director and Innovation Leader. He leads transformational
innovation projects that have the goal to shape the future of clinical trial execution, improve
the clinical trial experience and position Janssen as a role model in patient-centered clinical
Bert is an international industry expert in Clinical Research and Digital Health. He graduated
in Biomedicine and obtained a PhD in Medicine from Utrecht University. He worked in
Clinical Operations-, QA- and IT-management before joining Janssen’s Clinical Innovation
team in 2015.
His main focus today is developing capabilities for digital health in clinical trials, including
harmonization of digital outcome measures and technologies for remote patient monitoring
“Doina Sirbu is a Medical Device Innovation Lead at UCB, where her focus is to support the development of novel digital biomarkers and build strategies that would lead to their integration in clinical settings. She is an active member of Digital Medicine Society (DiMe) and a contributor to the Nocturnal Scratch digital measure development collaboration.
During her career, Doina acquired extensive experience in innovation in the pharmaceutical industry as well as in the field of start-ups. This double hatting allows her to work very closely with start-ups and tech companies while exploring collaborations with pharmaceutical companies to ultimately embed new technologies in a clinical environment.
Doina holds an engineering degree in Pharmaceutical Industry, a PhD in Medicinal Chemistry and a master’s in Business Innovation and Entrepreneurship.”
Ariel V. Dowling, PhD is a Director of Digital Strategy within the Data Sciences Institute at Takeda Pharmaceuticals. In this role, Ariel oversees the strategy, assessment, and deployment of digital devices and decentralized clinical trials across the organization. She was previously a Senior Clinical Data Scientist at Biogen Inc where she managed the wearable sensors deployed in clinical trials for Parkinson’s Disease. Ariel was the algorithm team lead at MC10 Inc and a senior research scientist at BioSensics LLC. Ariel holds an MS and PhD in Mechanical Engineering from Stanford University and an AB and BE in Mechanical Engineering from Dartmouth College. She currently serves on the Strategic Advisory Board of the Digital Medicine (DiMe) Society.
Marco Viceconti is full professor of Industrial Bioengineering in the department of Industrial Engineering of the Alma Mater Studiorum – University of Bologna, and Director of the Medical Technology Lab of the Rizzoli Orthopaedic Institute. In the IMI-funded Mobilise-D project he serves as academic lead of the regulatory workpackage, which is pursuing the regulatory qualification of digital mobility outcomes from wearable sensors as drug development tools.
Aude Clement, PharmD is a Global Program Regulatory Director within Novartis Global Drug Development organization. In this role, Aude contributes to the internal capability building and global regulatory policy efforts to embed the use of digital technologies and data in regulatory decision making for medicines. She provides strategic regulatory support to novel digital endpoints development programs. Aude previously worked at Roche, Sanofi and Pfizer, where she held various regulatory affairs roles supporting global drug development and registration across therapeutic areas and modalities.
Dr. Roozbeh Ghaffari is CEO and co-Founder of Epicore Biosystems, a digital health solutions company commercializing wearable microfluidic sensors and analytics for tracking and managing hydration, nutrition, and metabolic health biomarkers.
His contributions in soft bioelectronics, microfluidics and neuroscience have been recognized with the MIT100K Grand Prize, IEEE Spectrum Emerging Technology Prize, and the MIT Technology Review Magazine’s Top 35 Innovators Under 35.
He has published over 100 academic papers and is inventor on over 50 patents issued. Dr. Ghaffari graduated from MIT with BS and MEng degrees in Electrical Engineering and received his PhD in biomedical engineering from the Harvard-MIT Division of Health Sciences and Technology.
Stefan Avey is a Principal Data Scientist at Janssen R&D where he focuses on data analytics to further development of digital biomarkers and digital measurements for the Immunology therapeutic area.
Stefan has broad experience in setting digital health strategy, implementing digital health technologies in non-interventional and interventional clinical trials, digital health technology vendor management, and FDA/EMA regulatory interactions. He is a member of the Digital Medicine Society (DiMe) and contributor to the nocturnal scratch digital measures development project (https://www.dimesociety.org/tours-of-duty/digital-measures-nocturnal-scratch/). In addition, Stefan represents Janssen as the industry lead of the statistical inference, design, and learning work package for the IMI IDEA-FAST project (https://idea-fast.eu/).
Stefan holds a Ph.D. in Computational Biology & Bioinformatics from Yale University and dual Bachelor of Science degrees in Biomedical Mathematics and Computational Biology from The Florida State University.
For those of you attending in-person, we look forward to coming together in London this June. Working with the venue and following the guidelines from local and national authorities, we have developed robust COVID-19 mitigation protocols.
Our venue for Digital Biomarkers & Digital Measurements 2022 is One Birdcage Walk, a unique and elegant space nestled in the heart of London. This venue is surrounded by landmarks such as the Big Ben, Westminster Abbey and Buckingham Palace, and conveniently located just a short walk from transport links such as St James’s Park, Westminster and Victoria stations.
For online attendees, we will be running the event on the Hopin conference platform. Not only will you be able to view all the content as it happens, but you will also be able to network with both your fellow online attendees, as well as those in-person. You’ll also be able to pose your questions to the speaker faculty directly through the platform.
Partner with Us
Bringing together senior-level executives from across the industry, the Digital Biomarkers & Digital Measurements Summit promises an unrivalled networking and learning opportunity for everyone working in this space.
Digital Biomarkers & Digital Measurements provides a rare opportunity to showcase your offering to a dedicated, world-class audience. Spaces are limited this year, please contact our commercial manager, Christian (email@example.com) to discuss opportunities for involvement.
Register for the Event
For pricing and booking options please click the button to go to the registration page.